INTRODUCTION
Patients with cardioembolic stroke and stroke consequent to a specific condition (cerebral sinus venous thrombosis, dissection of intracranial arteries, hypercoagulable state) require urgent anticoagulation for secondary stroke prevention (1) (2) (3) (4) . This is important for prevention of arterial and venous thromboembolism, particularly of embolic stroke recurrences, and to reduce a high rate of in-hospital mortality in patients with recurrent embolism (19.6%) (5) (6) .
Despite the emergence of new anticoagulants, warfarin is a widely prescribed first-line anticoagulant for most causes of embolic stoke due to its effectiveness in the management of thromboembolism and to its low cost (7) (8) (9) .
Warfarin has narrow therapeutic index and at least 20-fold interpatient variations in dose requirements, which can lead to dose-related insufficient or excessive anticoagulation. Most dose-dependent adverse events emerge during introduction of therapy. Risk for hemorrhage or thromboembolism in this initiation period is higher than during later stages (event rates range from 16% to 25%) (10) (11) . Therefore, stroke patients that require anticoagulation are also at an increased risk of warfarin-dosage side effects and hence of recurrent stroke if they are underdosed or in overdosed conditions due to warfarin-induced brain hemorrhage (12) (13) .
Warfarin pharmacogenetics, association of CYP2C9 and VKORC1 gene polymorphisms and dosing algorithms which use this genetic information are well documented (14) (15) (16) (17) (18) .There are few studies available which have investigated the effectiveness of clinical application of genotype-guided dosing, and such studies conducted among acute stroke patients are specifically scarce (19) (20) (21) (22) . For these high-risk patients, it is essential to achieve stable anticoagulant effect as early as possible in order to prevent the risk of dosage-related complications by using the initial doses based on individual genotype (17, (23) (24) . The results of Franchini' s meta-analysis that included nine trials (2812 patients) show that genotypeguided initial warfarin dosing significantly reduced the risk ratio for developing major bleeding events, compared with the control group (RR=0.47; P=0.04), or reduced serious bleeding events by approximately 50% compared to clinically-guided dosing group (25) . Data obtained by meta-analysis of randomized clinical trials (Stergiopoulos et al.) indicated that a genotype-guided dosing strategy was not superior to clinical dosing algorithms in terms of INR values, reduction in major bleeding or thromboembolic events (26) .
Recently, several randomized controlled trials have been published with different conclusions on the clinical utility of genotype-guided dosing of coumarin anticoagulants. A study conducted by Pirmohamed group (EU-PACT trial) found that pharmacogenetic-based dosing was associated with a higher percentage of time in the therapeutic INR range than standard dosing during the initiation of warfarin therapy (27) , while Kimmel group (COAG trial) did not confirm these findings for the anticoagulation period of the first 4 weeks of warfarin therapy (28) . Also, Verhoef group did not confirm the findings for acenocoumarol or phenprocoumon during 12 weeks after the initiation of therapy in patients with atrial fibrillation or venous thromboembolism (29) .
In this study, we compared the impact of CYP2C9 and VKORC1 genotype-guided dosing of warfarin with a standardized, fixed dosing regarding anticoagulation control and clinical outcome in acute stroke patients during the first three weeks of therapy.
Patients and methods
During six months, 587 Croatian Caucasian patients (EUCs) with acute ischemic stroke were hospitalized at the Department of Neurology, UHC Zagreb. We conducted a prospective trial among 210 (36% of the total number) patients with an indication for urgent anticoagulation, whose initial brain CT scan was without signs of hemorrhage. Detailed inclusion and exclusion criteria are listed in Table 1 .
Power analysis was done before the study. If the statistical significance level is set to p<0. (Table 2a) .
Since the number of eligible patients, i.e. those with appropriate diagnosis for our study (N=210) was relatively low and inclusion/exclusion criteria practically did not have any impact on patient selection as each patient required equal treatment and was consequently to be allocated in one of two study arms, we used a simple way of grouping (distribution) patients by alternative allocation of every second patient into one of the two study arms.
Moreover, having in mind that we could not influence patient's occurrence and patient's disease status in any manner, we considered that any possible bias was absolutely negligible, by using this method of allocation.
Concomitant therapy and the number of smokers were similar in both groups. Once the ethical committee permission had been obtained, written informed consent form was provided for each PhG patient.
Using non-profit website published algorithm http: //www.WarfarinDosing.org., we assessed initial pharmacogenetically-predicted warfarin dose, introducing a loading-dose strategy of warfarin for each patient in PhG during the first two to five days, while subsequently patients were treated on the basis of the INR (28) (29) (30) . In the control group, warfarin was introduced by a fixed dose of 2 tablets of 3 mg warfarin (6 mg) for the first two to five days, and the doses 
Warfarin dosage side effects and clinical outcome
Warfarin-dosage side effects were classified into two groups. Group 1 included minor bleeding (asymptomatic microhematuria, slight gingival or vaginal bleeding, and subcutaneous hematoma). Group 2 included major bleeding which was classified into two subgroups: subgroup 2a) bleedings that did not require interruption of therapy, such as mild hemorrhagic transition of infarct zone without worsening of neurological deficit, and 6 subgroup 2b) bleedings that required interruption of warfarin therapy (large intracerebral hemorrhage with worsening of neurological deficit, extensive urogenital or gastrointestinal bleeding). Patients' neurological deficit on admission was estimated using the NIHSS scale (31). Clinical outcome defined as neurological deficit at the end of the study (follow-up period of three weeks) was assessed using mRS (32) .
Endpoints
The primary endpoints to determine by comparing the PhG and NPhG were as follows: The secondary endpoints were the following:
-time needed to achieve a stable maintenance dose -proportion of patients who achieved a stable maintenance dose depending on the day of measurement -incidence of warfarin dosage-side effects.
Genotyping procedures
DNA was isolated from whole blood by salting out method. Three SNPs were genotyped by 
Statistical Analysis
The analysis was carried out by using the statistical software package STATISTICA ver. 6 
Results
Demographic and clinical data, as well as primary and secondary endpoint results are presented in Table 2a and Table 2b . 
Primary endpoints
The groups differed significantly in the time needed to reach the target INR≥2 and in the average INR values depending on the day of measurement (p=0.00017) ( Figure 3 ).
We found no association of the final clinical outcome with the appearance of the dosagedependent side effects in PhG (p=0.1198), in contrast to the positive correlation in NPhG (p=0.0006). The association of clinical outcome with the appearance of complications was also confirmed by using Spearman correlation coefficients (rho=0.2617, p=0.0075).
Secondary endpoint
PhG achieved stable dose earlier, i. e. in 10 (9.9-10.7, 95% CI) days as compared to NPhG The groups differed in the proportion of patients who achieved stable maintenance dose depending on the time (p=0.000) (Figure 4 ).
Within seven days of the therapy introduction, 9.4% of PhG subjects achieved stable dose but none from the NPhG. On the 10 th day, cumulatively 59.5% of PhG subjects achieved stable dose as compared to 11.5% in NPhG. By the 12 th day, a total of 94.3% of PhG subjects had stable maintenance dose as opposed to 39.4% of NPhG subjects. After two weeks, 97.1% of PhG and 60.5% of NPhG subjects achieved stable dose.
Discussion
Our investigation is the only study conducted exclusively among patients with acute stroke that need urgent anticoagulation, except for individual case reports and some studies of warfarin dosing formula among stroke patients in the available literature (21, 23) . Goals of our study were to determine whether pharmacogenetically-guided warfarin dosing could improve respectively. CYP2C9 variant allele frequencies are also rather variable among racial groups (4% in Asians, 5% in blacks, 20% in whites), which may explain some of the population-level differences in application of warfarin-dosing algorithms in racial groups (37) (38) (39) (40) (41) .
Our data differ from a study conducted among orthopedic patients in which authors did not find any differences in the anticoagulation control or in the incidence of complications between PhG and NPhG (19) . In their study, 13% of patients had only CYP2C9 allelic variants, 44% of patients had VKORC1 polymorphisms, and 19% of patients had polymorphism for both genes, in contrast to our PhG group where polymorphism for only CYP2C9 gene was present in 32% of patients, 24.5% of patients had only the VKORC1 gene polymorphism, and 28.3% had polymorphism for both genes. This may contribute to differences of our results. In our study, serious complications were more frequent among carriers of VKORC1 1173C>T alleles (62.5%) and carriers of both defective CYP2C9*2 and *3 alleles (37.5%), but without significant difference between the genotypes.
Secondary endpoints (stable anticoagulant effects) were also achieved in our study. Data confirmed that genotype-guided introduction reduced the time required for stabilization, i.e.
PhG achieved a stable maintenance dose earlier, with greater proportion of stable anticoagulated patients depending on time as compared to NPhG. Our data demonstrated the difference between clinical outcome and the occurrence of complications between the two groups. We found no relations between the occurrence of warfarin-dosage side effects and the clinical outcome in PhG in contrast to positive correlation found in NPhG. This fact is probably associated with the occurrence of more severe bleeding in the fixed-dosing group of patients. There is still no sufficient evidence to support the use of pharmacogenetics to prevent major complications and improve clinical outcome (39) . The already mentioned different results obtained in several randomized controlled trials could be due to different approaches to dosing. EU-PACT trial applied fixed-dosing approach while clinical dosing algorithm was used in the COAG trial (27, 28) . Further, differences in the trial populations could have influence on study results, since additional variants discovered in African
Americans could contribute to dose requirements (40, 41) .The strength of our study lies in investigation of a homogenous population of acute ischemic stroke patients among whom atrial fibrillation was the most frequent indication for warfarin therapy. In addition, the study was conducted in hospital settings where experienced cerebrovascular neurologists comprehensively monitored patients with ischemic stroke (42) . Our data are consistent with the most recently published findings and remarks by Schwarz group (43). They found genotype-based dosing to be superior in patients who had atrial fibrillation as compared to patients who had venous thromboembolism, with the clear benefit when the participants harbored two or more variant alleles. This was the case in our study where homozygosity for "defective" variants of VKORC1 and CYP2C9 genes contributed to the earlier achievement of target INR and to the longest proportion of time spent within the therapeutic INR range in comparison to carriers of wild type alleles. This finding could be at least partly explained by the observation that "wild" type VKORC1 allele carriers can also be carriers of rare mutations and they require significantly higher doses, or can even develop resistance to warfarin.
However, these mutations are not analyzed in routine clinical practice (44) .
We are aware that a limitation of this study is a relatively small number of enrolled patients and that our results need to be confirmed by further studies on larger populations of patients.
Nevertheless, from the clinical point of view, we were able to detect clinically relevant differences. Our group of patients differed from respondents in other studies since they were in life-threatening condition due to the acute brain infarction, with an increased risk of bleeding and poor outcome due to the nature of the disease itself or because of warfarin-dosedependent over/under-anticoagulation. The risk of early embolic stroke recurrence range between 5-7% within the first week, with simultaneously increased risk of hemorrhagic transformation of an ischemic infarct related to the nature of the ischemic brain damage and the risk of warfarin-induced brain hemorrhage due to overanticoagulation (45, 46) . Data from our study confirmed faster anticoagulant control and, bearing in mind that acute stroke patients are at increased risk for recurrent embolism or warfarin-induced brain hemorrhage, we also confirmed safer anticoagulant control among them, with better clinical outcome and minor neurological deficit using genotype-guided warfarin dosing. This is important for the prevention of arterial and venous thromboembolism among acute stroke patients, particularly of embolic stroke recurrences.
Conclusion
Our study confirmed that initiating warfarin therapy with genotype-guided dosing has the greatest impact on anticoagulation control during the early stages of therapy introduction.
This individualized treatment reduces the time required for stabilization, which is important for fast and stable anticoagulation in clinical practice, particularly among stroke patients who are at increased risk of brain hemorrhage caused by the nature of the disease itself. At the same time, they undergo a high risk of warfarin-dose dependent events, risk of stroke recurrence due to embolisms in underdosed conditions, or warfarin-induced brain hemorrhage in overdosed state. We confirmed better clinical outcome with minor neurological deficit using CYP2C9 and VKORC1 genotype-guided dosing compared to fixed warfarin dosing.
Study Limitations
A limitation of the study might be the size of observed patient groups. Randomisation and concealment of allocation are limitations, and could have biased the results. The lack of knowledge on control subjects' genotype could have had impact on the results.
However, the obtained data indicated significant findings which need to be confirmed in replication studies and in other populations.
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